Clinical Trial Update: A Study to Test the Combination of Tiotropium and Olodaterol Using the Respimat® Inhaler in People With Chronic Obstructive Pulmonary Disease (COPD) Who Have Different Abilities to Inhale [Phase 4]

View source ↗

Summary

Phase 4 study evaluating a tiotropium and olodaterol combination delivered by Respimat in COPD patients with varying inhalation abilities; completed with result…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• olodaterol (olodaterol)
• tiotropium (tiotropium)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Pulmonary Disease, Chronic Obstructive | Phase 4 | Status: COMPLETED | Results posted: 2021-11-18